PubMed · 3674940
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
T J David. 1987. Steroid scare.. https://doi.org/10.1136/adc.62.9.876
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
Therapy of asthma with inhaled steroids in children becomes the main standard for treatment of asthmatic airway inflammation. Thus, in most children asthma is controlled by the new galenic formulations of topical inhalative corticosteroids. Dose-dependent side effects must be known and have to be detected by appropriate testing. In childhood the suppression of the hypothalamic-pituitary-adrenocortical axis and of growth is the main concern of steroid therapy. The latter depends on dose and duration of intake as well as the susceptibility of the growth phase during which the child inhales steroids. Today, doses of topical steroid up to about 800 micrograms/day seem to be safe. However, some cases with individual reactions to low doses of inhaled steroids are known: therefore, close clinical control of children on inhaled steroids is extremely important.
The increase in pulmonary vascular resistences in acute pulmonary thromboembolism (APT) is the consequence of anatomical obstruction and pulmonary artery constriction. The administration of inhaled nitric oxide (NO) may be therapeutically useful in acute pulmonary hypertension by APT given its limited vasodilator effect on pulmonary circulation. A patient with APT in whom this selective vasodilator effect was observed is presented. The authors suggest that the administration of inhaled NO may be a potentially beneficial coadjuvant therapy in acute pulmonary hypertension induced by APT.